

**REMARKS**

In the Office Action of July 16, 2004, the Examiner restricted the pending claims into patentably distinct inventions as follows:

- I. Claims 1-7 drawn to a pharmaceutical composition comprising at least one polymethoxyflavone and a suitable pharmaceutically acceptable diluent, carrier or adjuvant; and
- II. Claims 8-23 drawn to the use of and a method of treating a mammal having abnormalities resulting from insulin resistance comprising administering at least one polymethoxyflavone compound.

In response, Applicants hereby elect without traverse, claims 8-23 drawn to the use of and a method of treating a mammal having abnormalities resulting from insulin resistance comprising administering at least one polymethoxyflavone compound.

Claims 1-7 have been canceled without prejudice, as they are part of the non-elected invention.

This Response is being submitted within 30 (thirty) days from the mailing date of the Office Action. Accordingly, it is believed that no fee is due. However, if it is determined that any fee is due, the Examiner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

An early and favorable action on the merits is earnestly solicited.

Respectfully submitted,  
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 

Robert J. Paradiso, Reg. No. 41,240

Davidson, Davidson & Kappel, LLC  
485 Seventh Avenue  
New York, New York 10018  
(212) 736-1940